A fragment library screen was carried out to identify starting points for novel CDK8 inhibitors. Optimization of a fragment hit guided by co-crystal structures led to identification of a novel series of potent CDK8 inhibitors which are highly ligand efficient, kinase selective and cellular active. Compound 16 was progressed to a mouse pharmacokinetic study and showed good oral bioavailability.
Keywords: CDK8; Fragment-based drug discovery (FBDD); Inhibitor.
Copyright © 2017 Elsevier Ltd. All rights reserved.